Toxicity grades 2 to 4 according to WHO during treatment phases I, II, III, and IV, respectively, for patients treated according to the intensive-therapy protocol
| Toxicity . | Phase I . | Phase II . | Phase III . | Phase IV . |
|---|---|---|---|---|
| Number of evaluable patients | 274 | 215 | 214 | 211 |
| Infectious | 42 (3) | 52 (1) | 55 (2) | 18 (1) |
| Gastrointestinal | 8 (1) | 11 (0) | 53 (3) | 3 (0) |
| Cardiopulmonary | 4 (1) | 1 (0) | 1 (0) | 1 (1) |
| Neurological/mental | 9 (1) | 3 (0) | 7 (1) | 12 (0) |
| Other4-150 | 14 (0) | 3 (0) | 3 (0) | 14 (1) |
| Toxicity . | Phase I . | Phase II . | Phase III . | Phase IV . |
|---|---|---|---|---|
| Number of evaluable patients | 274 | 215 | 214 | 211 |
| Infectious | 42 (3) | 52 (1) | 55 (2) | 18 (1) |
| Gastrointestinal | 8 (1) | 11 (0) | 53 (3) | 3 (0) |
| Cardiopulmonary | 4 (1) | 1 (0) | 1 (0) | 1 (1) |
| Neurological/mental | 9 (1) | 3 (0) | 7 (1) | 12 (0) |
| Other4-150 | 14 (0) | 3 (0) | 3 (0) | 14 (1) |
The figures indicate the percentages of patients starting each phase who sometime during the phase experienced WHO grade 2 to 4 toxicity (within brackets grade 4 toxicity only).
Other includes metabolic (e.g., diabetes mellitus, hypothyreosis), thromboembolic, musculoskeletal, skin (including damage caused by extravasation of cytostatics), liver, urogenital, and hematologic (excluding expected cytopenia after chemotherapy).